In line with these findings recently introduced CXCR4-targeted PET/CT imaging by means of the high affinity CXCR4 ligand [68Ga]-Pentixafor [13, 14] has been already proven to be complementary for diagnostic use in myeloma patients [15] compared to standard [18F]FDG-PET/CT [16]. This evidence concerns the gene CXCR4 and plasma cell myeloma.